
Corvus Pharmaceuticals
Clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer.
Market cap
$403m
Enterprise value
$330m
Share price
$5.41 CRVS
Authorizing premium user...